These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18315450)

  • 1. Ziprasidone in adolescents with autism: an open-label pilot study.
    Malone RP; Delaney MA; Hyman SB; Cater JR
    J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):779-90. PubMed ID: 18315450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Retrospective Naturalistic Study of Ziprasidone for Irritability in Youth with Autism Spectrum Disorder.
    Dominick K; Wink LK; McDougle CJ; Erickson CA
    J Child Adolesc Psychopharmacol; 2015 Jun; 25(5):397-401. PubMed ID: 26091194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.
    Zhao T; Park TW; Yang JC; Huang GB; Kim MG; Lee KH; Chung YC
    Int Clin Psychopharmacol; 2012 Jul; 27(4):184-90. PubMed ID: 22426471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
    Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case series: use of ziprasidone for maladaptive symptoms in youths with autism.
    McDougle CJ; Kem DL; Posey DJ
    J Am Acad Child Adolesc Psychiatry; 2002 Aug; 41(8):921-7. PubMed ID: 12164181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder.
    DelBello MP; Versavel M; Ice K; Keller D; Miceli J
    J Child Adolesc Psychopharmacol; 2008 Oct; 18(5):491-9. PubMed ID: 18928413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Ratner Y; Gibel A; Yorkov V; Ritsner MS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder.
    Owen R; Sikich L; Marcus RN; Corey-Lisle P; Manos G; McQuade RD; Carson WH; Findling RL
    Pediatrics; 2009 Dec; 124(6):1533-40. PubMed ID: 19948625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment.
    Cohen SA; Fitzgerald BJ; Khan SR; Khan A
    J Clin Psychiatry; 2004 Jan; 65(1):110-3. PubMed ID: 14744179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of switching to ziprasidone in italian patients with acute exacerbation of schizophrenia: an open-label trial.
    Mencacci C;
    Pharmacopsychiatry; 2012 Sep; 45(6):236-40. PubMed ID: 22592506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
    Olié JP; Spina E; Murray S; Yang R
    Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.
    Stigler KA; Diener JT; Kohn AE; Li L; Erickson CA; Posey DJ; McDougle CJ
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):265-74. PubMed ID: 19519261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
    Zimbroff D; Warrington L; Loebel A; Yang R; Siu C
    Int Clin Psychopharmacol; 2007 Nov; 22(6):363-70. PubMed ID: 17917555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano R; O'Gorman C; Harrigan RH
    Pharmacotherapy; 2010 Feb; 30(2):127-35. PubMed ID: 20099987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder.
    Biederman J; Mick E; Spencer T; Dougherty M; Aleardi M; Wozniak J
    Bipolar Disord; 2007 Dec; 9(8):888-94. PubMed ID: 18076539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective chart review of intramuscular ziprasidone for agitation in children and adolescents on psychiatric units: prospective studies are needed.
    Barzman DH; DelBello MP; Forrester JJ; Keck PE; Strakowski SM
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):503-9. PubMed ID: 17822344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone.
    Scahill L; Blair J; Leckman JF; Martin A
    J Psychopharmacol; 2005 Mar; 19(2):205-6. PubMed ID: 15728441
    [No Abstract]   [Full Text] [Related]  

  • 19. Psychosocial functioning and health-related quality of life in children and adolescents treated with open-label ziprasidone for bipolar mania, schizophrenia, or schizoaffective disorder.
    Stewart M; DelBello MP; Versavel M; Keller D
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):635-40. PubMed ID: 20035581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ziprasidone: the fifth atypical antipsychotic.
    Caley CF; Cooper CK
    Ann Pharmacother; 2002 May; 36(5):839-51. PubMed ID: 11978164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.